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The human TEAD family of transcription factors
(TEAD1–4) is required for YAP-mediated transcrip-
tion in the Hippo pathway. Hyperactivation of TEAD’s
co-activator YAP contributes to tissue overgrowth
and human cancers, suggesting that pharmacolog-
ical interference of TEAD-YAP activity may be an
effective strategy for anticancer therapy. Here we
report the discovery of a central pocket in the YAP-
binding domain (YBD) of TEAD that is targetable by
small-molecule inhibitors. Our X-ray crystallography
studies reveal that flufenamic acid, a non-steroidal
anti-inflammatory drug (NSAID), binds to the central
pocket of TEAD2 YBD. Our biochemical and func-
tional analyses further demonstrate that binding
of NSAIDs to TEAD inhibits TEAD-YAP-dependent
transcription, cell migration, and proliferation, indi-
cating that the central pocket is important for TEAD
function. Therefore, our studies discover a novel
way of targeting TEAD transcription factors and set
the stage for therapeutic development of specific
TEAD-YAP inhibitors against human cancers.
INTRODUCTION
The Hippo pathway controls organ size by blocking cell prolifer-
ation and promoting apoptosis (Hansen et al., 2015; Wacke-
rhage et al., 2014). Two homologous oncoproteins, YAP and
TAZ, are the major downstream targets inhibited by the Hippo
signaling network. YAP/TAZ interact with the TEA domain tran-
scription factors (TEADs) to promote cell growth and proliferation
and inhibit apoptosis. In humans, there are four closely related
TEAD proteins, TEAD1–4. All four TEADs contain an N-terminal
TEA domain that binds DNA and a C-terminal YAP-binding
domain (YBD) that binds to YAP/TAZ (Figure 1A). Because
TEADs do not contain an activation domain and YAP/TAZ2076 Structure 23, 2076–2086, November 3, 2015 ª2015 Elsevier Ltddo not contain a DNA-binding domain, TEADs and YAP/TAZ
together form a functional heterodimeric transcription complex
that activates the expression of Hippo-responsive genes critical
for tissue homeostasis, stem cell regeneration andmaintenance,
and tumorigenesis (Pobbati and Hong, 2013).
Genetic studies have shown that TEAD-YAP promotes cell
proliferation and inhibits cell death (Hong and Guan, 2012; Sa-
wada et al., 2008). Hyperactivation of TEAD-YAP contributes
to various human cancers, such as prostate cancer (Knight
et al., 2008) and pancreatic cancer (Hucl et al., 2007; Kapoor
et al., 2014). TEADs also bind to the Vgll family of proteins that
modulates YAP oncogenic function (Jiao et al., 2014; Pobbati
et al., 2012; Pobbati and Hong, 2013). For cancers to progress,
cells need to possess certain attributes (Hanahan andWeinberg,
2011). Remarkably, YAP and TAZ, with the help of TEADs,
endow cells with many such attributes, such as resistance to
contact inhibition (Zhao et al., 2007), ability to sustain anchorage
independent growth (Overholtzer et al., 2006), transition to a
mesenchymal state for migration, invasion and maintenance of
stemness (Chan et al., 2008; Diepenbruck et al., 2014; Lei
et al., 2008), and ability to survive in suspension or resistance
to anoikis for metastasis (Lamar et al., 2012; Zhao et al., 2012).
To achieve this effect, the TEAD-YAP/TAZ complexes upregu-
late the expression of a myriad of target genes involved in anti-
apoptosis and proliferation, such as CTGF (Zhao et al., 2008),
Cyr61 (Zhao et al., 2008), c-Myc (Dong et al., 2007), Axl (Xu
et al., 2011), and Jagged1 (Tschaharganeh et al., 2013). There
is also a good correlation between YAP/TAZ overexpression or
nuclear localization and poor prognosis in various cancers (Mo-
roishi et al., 2015). Taken together, YAP and TAZ are potential
targets for cancer therapy.
Targeting an intracellular protein is conventionally achieved
through binding of small-molecule drugs to inhibit the activity
of the target protein. For a small molecule to bind, the protein
should possess a pocket with certain electrostatic and geomet-
ric properties. The available structures of YAP and TAZ indicate
that they do not have such a pocket and are therefore not
deemed targetable by small molecules. This is generally the
case for more than 90% of the proteins. However, we noticed
that the YAP-binding domain (YBD) of TEADs has a pocket inAll rights reserved
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Figure 1. The YAP-Binding Domain of TEADs
Has a Central Pocket
(A) Domain architecture of TEAD1 and YAP. All four
TEAD genes have an N-terminal DNA-binding TEA
domain and a C-terminal YAP-binding domain
(YBD). YAP has an N-terminal TEAD-binding
domain (TBD) followed by one or two WW domains
and a C-terminal activation domain.
(B) The crystal structure of the TEAD-YAP complex
(PDB: 3KYS) reveals three interfaces between TEAD
and YAP. TEAD YBD is colored green and YAP
TBD magenta. TEAD YBD has a large pocket in the
center (red ellipse); the hydrophobic volume of this
pocket is shown in yellow. On both ends of this
pocket are hydrophilic areas, shown in red and blue,
which could be used to improve the specificity of
TEAD-binding drugs. All structural figures were
generated with the Schro¨dinger software suite or
Chimera (UCSF).
(C) ITC showing heat response during TEAD-YAP
interaction. The binding affinity (Kd) between the
YAP peptide 1 and TEAD is indicated.
(D) Sequences and binding affinities of the YAP
peptides used in this study. Residues from in-
terfaces 2 and 3 are underlined.
(E) Summary of the results from the fragment library
screen.the center of the protein that appears to be druggable. TEAD
YBDhas been shown to bind YAP/TAZ through a defined surface
(Chen et al., 2010; Li et al., 2010; Tian et al., 2010). Because YAP/
TAZ relies on TEADs for activating gene expression, inhibiting
the oncogenic activities of YAP/TAZ can be achieved by directly
targeting TEAD-YAP protein-protein interactions or by inhibiting
the activity of TEADs. Another impetus for focusing on TEADs is
that TEADs appear to be largely dispensable for tissue homeo-
stasis in adults (Liu-Chittenden et al., 2012); therefore, inhibiting
TEADs should not perturb normal tissue growth or result in major
adverse toxicity effects.
Themajority of drugs or drug candidates that potentially target
the Hippo pathway affect the nucleocytoplasmic transport of
YAP/TAZ (Johnson and Halder, 2014; Park and Guan, 2013).
These include: GPCR agonists, such as dobutamine (Bao et al.,
2011); inhibitors of ILK (Serrano et al., 2013), PI3K (Fan et al.,
2013), andROCK (Dupont et al., 2011) kinases; statins that inhibit
3-hydroxy-3-methylglutaryl-coenzyme A reductase (Sorrentino
et al., 2014); and compounds, such as forskolin and rolipram
(Yu et al., 2013), that increase cyclic AMP levels. As diverse
cellular signals regulate YAP/TAZ nucleocytoplasmic transport,
and as these regulator proteins are also involved in other impor-
tant cellular signaling networks, it is unclear whether these com-
pounds could be effective in treating cancers caused by a defec-
tiveHippopathway. There are also reportedmolecules that could
disrupt TEAD-YAP interactions, such as verteporfin (Liu-Chitten-
den et al., 2012) and cyclic YAP peptides (Zhang et al., 2014), but
these molecules suffer from having a low plasma half-life or cell-
penetrating ability. Therefore, there is an urgent need to find new
strategies for developing drugs against human cancers caused
by a dysregulated Hippo pathway.Structure 23, 2076–20In this study, using both computational and experimental
approaches, we have evaluated the targetability of the YAP-
binding domain (YBD) of TEADs. We show that TEAD YBD
binds to flufenamates (non-steroidal anti-inflammatory drugs
[NSAIDs]) with appreciable affinity. We have determined the
crystal structure of TEAD2 YBD bound to flufenamic acid
(FA), which reveals that flufenamates bind to the central pocket
of TEAD. We also show that flufenamates, such as FA and
niflumic acid (NA), can inhibit both TEAD function and TEAD-
YAP-dependent processes, such as cell migration and prolif-
eration. Taken together, our studies bring to light the critical
function of the central pocket in TEADs that is generally over-
looked in the field, and suggest that it is biologically relevant
to target the central pocket of TEADs for anticancer therapy.
Our work has therefore established the basis for future devel-
opment of more potent and specific TEAD-YAP inhibitors to
treat human cancers.
RESULTS AND DISCUSSION
The YAP-Binding Domain of TEAD Has a Central Pocket
TEADs (TEAD1–4) all have anN-terminal TEAdomain and aC-ter-
minal YAP-binding domain (YBD) (Figure 1A). TEADs bind to tran-
scription co-activator YAP through the YBD. YAP binds to TEADs
through the N-terminal TEAD-binding domain (TBD). YAP TBD is
followed by one or two WW domains and an activation domain
(Figure 1A). The TEAD-YAP complexes regulate the transcription
of Hippo-responsive genes to promote cell proliferation and
inhibit apoptosis. Hyperactivation of TEAD-YAP causes tumors;
therefore, the TEAD-YAP complexes are promising targets for
cancer treatment.86, November 3, 2015 ª2015 Elsevier Ltd All rights reserved 2077
For drug development, TEAD appears to be a suitable target.
TEAD YBD has a central pocket that is very hydrophobic and
seems druggable (Figure 1B). The amino acid residues lining
the central pocket are well conserved (Figure S1). The volume
of the central pocket is large enough to bind and fully envelop a
small molecule. The central pocket also has an excellent drugg-
ability score, Dscore = 1.39 (Halgren, 2009), meaning that it has
the right electrostatics and enclosure for binding drug-like mole-
cules with high affinity. Therefore, TEADs belong to the small
group of proteins that have an internal druggable pocket.
YAP binding requires a surface pocket on TEAD YBD that is
located at the back of the seven-stranded b sheet (Figure 1B)
(Tian et al., 2010). However, this surface pocket does not have
a good druggability score. Careful inspection of the crystal struc-
tures of TEAD1-YAP (PDB: 3KYS) and TEAD4-YAP (PDB: 3JUA)
reveals that the YAP-binding site is formed by a shallow surface
that cannot provide enclosure for a small molecule. Although in
theory the surface of TEADs could be potentially targeted by
small molecules to prevent its interaction with YAP, the absence
of deep pockets with good druggability scores will likely make it
very challenging to develop potent inhibitors to disrupt the
TEAD-YAP protein-protein interactions.
Fragment Screen for TEAD4 YBD
We have used human TEAD4 YBD to biochemically analyze the
druggability of the TEAD proteins. TEAD4 YBD is well folded,
and is both necessary and sufficient to interact with YAP/TAZ
(Chen et al., 2010; Li et al., 2010; Tian et al., 2010). It also has
the hydrophobic central pocket. Unlike the full-length TEAD4
protein, sufficient quantities of purified recombinant TEAD4
YBD could be obtained.
We next evaluated whether the TEAD4-YAP interaction is
conducive for disruption by small-molecule drugs. Because
TEADs and YAP form a functional transcriptional heterodimer,
disruption of TEAD-YAP interactions will hamper cell prolifera-
tion. However, the interactions between TEADs and YAP are
quite extensive, involving three interfaces with YAP encircling
roughly three-quarters of TEAD YBD (Figure 1B). For drug devel-
opment, it would be beneficial to identify the hot spots that
contribute mainly to the binding affinity between TEADs and
YAP. To do this, we used several YAP peptides spanning various
boundaries at interfaces 2 and 3, and measured their affinity
toward TEAD4 YBD using isothermal titration calorimetry (ITC).
We did not use the YAP peptides containing residues in interface
1 because it has been shown that interface 1 is dispensable for
YAP binding (Chen et al., 2010; Tian et al., 2010).
The YAP peptide that contains interface-2 and -3 residues
(peptide 1) interacts with TEAD4 YBD with a nanomolar affinity
(Figure 1C), which is in line with the findings of our previous study
(Tian et al., 2010). Therefore, it seems plausible to predict that a
small molecule that binds to TEADs with lower nanomolar affinity
should be able to disrupt the TEAD-YAP interactions.We noticed
that the YAP peptides containing only interface-2 residues did
not bind to TEAD4 YBD (Figure 1D). The YAP peptide containing
only interface-3 residues (peptide 5) had very weak binding to
TEAD4 YBD with a dissociation constant (Kd) of about 77 mM
(Figure 1D), which is about 350-fold weaker than that of the
YAP peptide containing interfaces 2 and 3 (peptide 1). This sug-
gests that interface 3 is the major YAP-binding site but that inter-2078 Structure 23, 2076–2086, November 3, 2015 ª2015 Elsevier Ltdface 2 is also required for more efficient binding. However, the
distance between interfaces 2 and 3 imposes a lower size limit
on a dual-site ligand that is larger than what is generally deemed
acceptable for small drug-like molecules (Veber et al., 2002).
Furthermore, interface 3 has a poor predicted druggability score.
For these reasons, we decided to focus our effort on targeting
the hydrophobic central pocket of TEADs.
The central pocket of TEADs has an excellent druggability
score, mainly due to its enclosure and high hydrophobicity.
This led us to believe that a fragment-based screen would be a
viable approach for testing the druggability of the central pocket
of TEADs. Interestingly, the crystal structure of TEAD2 YBD (Tian
et al., 2010) shows that there is an opening at the surface of
TEAD2 YBD that is capable of allowing small molecules to ac-
cess the central pocket. In fact, some small molecules used in
the crystallization buffers were found to occupy the central
pocket of TEADs.
To experimentally verify the druggability of TEADs, we
screened our in-house fragment library. These compounds are
small molecules of about 150–300 Da in mass, and are used to
test the druggability of proteins (Hung et al., 2009). Qualitative
binding of fragments to TEAD4 YBD was evaluated using
differential scanning fluorimetry (DSF). Change in the melting
temperature (Tm) of TEAD4 YBD in the presence of fragments
is indicative of binding (Lo et al., 2004). Among the 800 com-
pounds screened, 33 were found to increase the Tm of TEAD4
YBD, giving a hit rate of about 4% (Figure 1E). We obtained
similar hit rates in the fragment-based screens of more conven-
tional drug targets, such as kinases (our unpublished data).
Therefore, our data strongly suggest that the YBD of TEADs is
druggable by small molecules. The high hit rate from the frag-
ment screen raises the possibility that small molecules bind to
the central pocket as opposed to the surface of TEAD YBD.
Identification of Flufenamic Acid as a
TEAD-Binding Drug
Encouraged by the results from the initial fragment screen, we
proceeded to screen a Pharmakon library that contained a
collection of US Food and Drug Administration-approved drugs
to identify more potent drugs that bind to TEAD4 YBD. We found
that a small portion of these drugs increased the Tm of TEAD4
YBD (Figure 2A). The hit rate was found to be much lower than
that of the fragment screen, as the Pharmakon library contained
larger and more complex molecules. We identified flufenamic
acid (FA) as the best hit in the Pharmakon screen (Figure 2B).
FA is used to treat inflammation and belongs to a class of flufe-
namates known as NSAIDs.
We also confirmed the binding of FA to TEAD4 YBD qualita-
tively through saturation-transfer difference (STD) nuclear mag-
netic resonance (NMR) spectroscopy (Begley et al., 2013). Addi-
tion of TEAD4 YBD triggered a positive signal in the STD
spectrum of FA, which was indicative of binding (Figure 2C). Us-
ing ITC, we were able to measure the Kd between FA and TEAD4
YBD, which is about 73 mM (Figure 2D). Thus, the TEAD protein is
directly targetable by small-molecule drugs.
Structure of the TEAD2-Flufenamic Acid Complex
Having confirmed FA binding to TEAD4 YBD qualitatively
and quantitatively (Figure 2), we were interested to locate theAll rights reserved
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Figure 2. Identification of Flufenamic Acid
as a TEAD-Binding Drug
(A) Summary of the results from the Pharmakon
library screen.
(B) Structure of FA.
(C) Saturation-transfer difference (STD) nuclear
magnetic resonance (NMR) spectra of FA showing
a conspicuous change after the addition of TEAD.
Upper trace shows the 1D 1H NMR spectrum of
free FA.Middle and lower traces are STD spectra of
FA in the absence and presence of TEAD.
(D) ITC measurement of the affinity (Kd) between
TEAD and FA.FA-binding site of TEADs. Based on our druggability assessment
of TEADs, we postulated that FA very likely binds to the hydro-
phobic central pocket. To test our hypothesis, we determined
the crystal structure of FA-bound human TEAD2YBD (Figure 3A).
There are two molecules of TEAD2 YBD per asymmetric unit in
the crystal and, reassuringly, FA is seen in the central pocket
of both TEAD2 molecules. A cross section of TEAD2 YBD with
FA occupying the central pocket is shown in Figure 3B. FA could
be nicely fitted to the omit electron density map that is observed
in the TEAD2 central pocket (Figure 3C).
A closer look at the TEAD2-FA structure revealed that the hy-
drophobic portions of FA make contacts with hydrophobic resi-
dues lining the central pocket (Figure 3D). The carboxylate group
of FA binds to an area where TEAD2 would interact favorably
with an electronegative group. The steric and electrostatic com-
plementarities between FA and the TEAD2 central pocket sup-
port the validity of the TEAD2-FA structure.
To further confirm that the density observed in the central
pocket indeed corresponded to the FA molecule, we also crys-
tallized TEAD2 YBD in the presence of bromofenamic acid
(BFA), an FA derivative in which the fluorines are replaced by
bromine. Bromine scatters X-rays anomalously, and this prop-
erty is commonly used in X-ray crystallography to locate the po-
sition of bromine atoms and thereby the bromoderivatives in the
crystal. As bromine is a much larger atom than fluorine, in our
BFA we replaced the trifluoromethyl group with one bromine
atom. We then solved the crystal structure of BFA-bound
TEAD2 YBD (Figure 4A). As expected, BFA (molecule 1) binds
to the central pocket of TEAD2 YBD in the same way as FA
does. This result confirms that FA indeed binds to the central
pocket of TEAD2 YBD. The data collection and refinement
statistics for the TEAD-FA and TEAD-BFA structures are shown
in Table 1.
Surprisingly, on the surface of one of the two TEAD2 mole-
cules in the asymmetric unit of the TEAD2-BFA structure, weStructure 23, 2076–2086, November 3, 2015found a second molecule of BFA (mole-
cule 2) (Figure 4A). We noticed that the
second BFA molecule is located close to
interface 3 of the TEAD-YAP complex.
However, we only observed partial den-
sity for this second BFA molecule, sug-
gesting that BFA might not fully occupy
this site and binds to interface 3 with
much weaker affinity. Furthermore, acareful inspection of the TEAD2-FA structure suggests that a
second FA molecule also binds to the interface-3 region of
TEAD2 YBD. This indicates that small-molecule inhibitors can
also bind to the surface pocket of TEAD YBD but perhaps with
weak affinity.
Specificity of the TEAD-Fenamate Interactions
After confirming that the molecule in the central pocket is indeed
FA, we examined in detail the interactions between FA and
TEAD2 YBD. There are 14 residues of TEAD2 YBD, mostly hy-
drophobic, within 4A˚ distance of FA (Figure 3D). FAmostly forms
hydrophobic interactions with these residues. However, there is
also a hydrogen bond between the carboxylate group in FA and
the main-chain amide nitrogen of C380, as well as a putative salt
bridge between the carboxylate group in FA and K357 in TEAD2
YBD (Figure 3D). As expected, the trifluoromethyl group inter-
acts with the neighboring hydrophobic residues. Five residues
in TEAD2 YBD contact the fluorines in FA, including A235,
V252, F428, F233, and L383. Residues I408, L383, F233, and
Q410 contact the rest of the trifluoromethyl-benzene ring. The
benzoic acid part of FA makes contact with residues S345,
V355, V329, V347, C380, M379, and K357 in TEAD2 YBD.
To further evaluate the specificity of the TEAD-FA interactions,
we decided tomutate the FA-interacting residues in TEAD4 YBD.
Based on the TEAD2-FA structure, an A235I and C380P double
mutation (dm) of TEAD2 is expected to sterically interfere with
FA binding (Figure 3D). Therefore, we made a corresponding
dmmutant in TEAD4 YBD (TEAD dm, A231I and C367P). We first
testedwhether the TEADdmcould fold properly. Proper folding is
needed to maintain the YAP-binding interface on TEAD4 YBD.
ThebindingbetweenTEAD4YBDandYAPwasassayedbynative
gel using TEAD4 YBD and a fluorescently labeled YAP peptide
(peptide 1). The mobility of the YAP peptide is shifted due to its
interaction with wild-type TEAD4 YBD (TEAD WT) (Figure 4B).
Indeed, TEAD dm interacts with YAP with similar efficiency asª2015 Elsevier Ltd All rights reserved 2079
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Figure 3. Structure of the TEAD2-FA
Complex
(A) Crystal structure of the TEAD2-FA complex re-
veals that FA binds to the central pocket in TEAD.
TEAD2 YBD is colored green. FA is shown as pink
sticks.
(B) A cross section of the surface drawing of TEAD2
YBD shows FA occupying the central pocket.
(C) Simulated annealing omit map contoured at 1s
for FA.
(D) Detailed view of the TEAD-FA interaction. FA
and FA-contacting residues in the central pocket
are shown as pink and gray sticks, respectively. The
hydrogen bond between FA andC380 is shown as a
green dotted line.TEAD WT does (Figure 4B), indicating that TEAD dm is properly
folded. We then measured the affinity between TEAD dm and
FA using ITC (Figure 4C). As predicted, TEAD dm binds to FA
moreweakly than TEADWT, validating the observed interactions.
TEAD Binds to Niflumic Acid
We next set out to test commercially available FA analogs,
aiming to find compounds with higher affinity for TEAD. We
measured affinities of various FA analogs toward TEAD4 YBD
using ITC (Figure 4D). The FA analog that binds to TEAD4 YBD
with the highest affinity is niflumic acid (NA) (Figure 4E). NA is
structurally similar to FA, except that it has nicotinic acid in
place of benzoic acid. Because we could not obtain the crystal
structure of NA-bound TEAD, we docked NA into the TEAD-FA
structure using FA as a template and observed that the heterocy-
clic nitrogen does not contact any residues. To understand the
basis for improved affinity observed for NA, we conducted a
conformational analysis on FA and NA. We observed that the
conformation of docked NA in the NA-TEAD complex is closer
to its minimal conformational energy, as compared with the
conformation of TEAD-bound FA (Figure 4F). The decreased
conformational energy might be the reason for the improved af-
finity of NA toward TEAD. The strain energies of different ligands
of TEAD are listed in Table 2.
Biological Consequence of Fenamate Binding to TEADs
We next tested the biological consequence of flufenamate bind-
ing to TEADs. The effect of flufenamate binding on TEAD-YAP
interaction was first assayed by native gel using TEAD4 YBD
and a fluorescently labeled YAP peptide. The YAP peptide
interactedwith TEAD4YBDwith similar efficiency in the presence
of the flufenamate drugs (FA or NA), indicating that TEAD-YAP
interaction is unaffected by flufenamate binding in vitro (Fig-2080 Structure 23, 2076–2086, November 3, 2015 ª2015 Elsevier Ltd All rights reservedure 5A). Our data also suggested that bind-
ing of FA or NA does not cause any confor-
mational change at the YAP-binding
surface of TEAD.
The central pocket of TEAD is seen
in three available TEAD YBD structures,
including TEAD1 (PDB: 3KYS), TEAD2
(PDB: 3L15), and TEAD4 (PDB: 4EAZ).
The residues lining the central pocket are
well conserved among TEAD genes fromvarious species (Figure S1). Thus, it is plausible to assume that
the conserved central pocket is important for the biological func-
tion of TEADs.We hypothesized that flufenamates, through bind-
ing to the central pocket, might disrupt the biological activity of
TEADs. To test this hypothesis,wemeasured theTEAD transcrip-
tional activity in the presence of FA or NA using a TEAD reporter
construct (Dupont et al., 2011). The TEAD-binding sites are
placed upstream of a luciferase reporter; therefore, the expres-
sion level of luciferase correlates with TEAD transcriptional activ-
ity. We observed a significant decrease in luciferase expression
level in the presence of the flufenamates FA and NA (Figure 5B).
This suggests that FA andNA indeed compromise TEAD function
in vivo. We next examined TEAD-YAP-mediated expression of
Hippo-responsive genes after FA treatment. Expression levels
of Hippo-responsive genes, such as NF2, Axl, and Jagged1,
were greatly reduced after FA treatment in MCF10A cells (Fig-
ure 5C). To ascertain that the observed reduction in gene expres-
sionswasdue to TEADbinding and notmediated by other targets
of NSAIDs, we tested the expression levels of these genes after
treating the cells with mefanamic acid (MA), another NSAID that
does not bind to TEAD (Figure 4D). Reassuringly, the Hippo-
responsive gene expressionwas reduced only in FA-treated cells
but not in MA-treated cells (Figure 5C). Because we did not
observe the disruption of TEAD-YAP interactions by FA and NA
in vitro, it is not clear how flufenamates, such as FA, inhibit the
TEAD-YAP-mediated gene expression. Future experiments are
needed to address this important question.
Since the Hippo-responsive genes promote cell migration and
proliferation, we next tested whether cell migration and prolifer-
ation were affected in the presence of FA and NA. Interestingly,
we observed significant reduction in cell migration and prolif-
eration after treating cells with these flufenamate drugs (Figures
5D and 5E). These results suggest that cellular processes
A B
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Figure 4. Specificity of the TEAD-Fenamate Interactions
(A) Crystal structure of the TEAD2-BFA complex. Molecule 1 of BFA binds to the central pocket. Molecule 2 of BFA binds to the YAP-binding interface 3 region of
TEAD2. TEAD2 YBD is colored green. BFA is shown as pink sticks.
(B) Monitoring TEAD-YAP interaction using TEAD4 YBD and a fluorescent-labeled YAP peptide. The native gel shows that TEADwild-type (WT) and TEAD double
mutant (dm) interact with YAP with similar efficiency.
(legend continued on next page)
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Table 1. Data Collection and Refinement Statistics for TEAD2-FA
and TEAD2-BFA Structures
Data Collection
Crystal TEAD2-FA TEAD2-BFA
Space group C2 C2
Wavelength (A˚) 0.97918 0.91925
Unit cell
a, b, c (A˚) 120.82, 61.45,
80.42
121.47, 61.58,
80.42
b () 117.55 117.70
Resolution
range (A˚)
50.0–2.30
(2.34–2.30)
40.0–2.18
(2.22–2.18)
Unique
reflections
20,054 (1,222) 24,263 (1,480)
Multiplicity 5.1 (4.5) 4.0 (3.1)
Data
completeness (%)
99.7 (99.7) 98.4 (86.6)
Rmerge (%)
a 11.9 (100) 5.4 (43.9)
I/s(I) 17.2 (3.39) 24.0 (3.14)
Refinement Statistics
Resolution
range (A˚)
33.7–2.30
(2.43–2.30)
38.7–2.18
(2.27–2.18)
No. of reflections
Rwork/Rfree
20,053/1,002
(1,222/60)
24,260/1,213
(1,480/74)
Data
completeness (%)
86.2 (55.0) 88.1 (55.0)
Atoms (non-H protein/
solvent/inhibitor)
3,304/85/60 3,304/109/51
Rwork (%) 17.1 (22.4) 17.9 (21.2)
Rfree (%) 23.2 (27.4) 22.7 (26.8)
Rmsd bond length (A˚) 0.015 0.015
Rmsd bond angle () 1.55 1.50
Mean B value (A˚2)
(protein/solvent/inhibitor)
44.7/40.3/60.2 45.0/44.8/63.5
Ramachandran plot (%)
(favored/additional/disallowed)b
97.9/2.1/0.0 97.2/2.8/0.0
Statistics for the highest-resolution shell are shown in parentheses.
Rmsd, root-mean-square deviation.
aRmerge = 100 ShSijIh, i  hIhij/ShSiIh, i, where the outer sum (h) is over
the unique reflections and the inner sum (i) is over the set of independent
observations of each unique reflection.
bAs defined by the validation suite MolProbity.
Table 2. Strain Energies of Co-crystallized Ligands (kJ/mol)
OPLS-2005
B3LYP
LAV3P**
B3LYP
LACV3P**
B3LYP
LAC3P**++
Niflumic acid 1.1 10.0 8.2 6.1
Flufenamic acid 4.6 19.0 17 15.8
Bromofenamic acid 3.4 7.7 6.2 5.2dependent on gene expression and driven by TEAD-YAP are
also affected by flufenamate treatment.
We next evaluated whether flufenamates, such as FA, could
also inhibit the expression of genes that were induced by YAP
overexpression. We generated the stable MCF10A cells that
express YAP S127A, the Hippo refractory mutant of YAP. The
expression levels of genes, such as Axl and NF2, were measured(C) The affinity (Kd) between FA and TEAD dm was measured by ITC.
(D) Structures of FA analogs and their binding affinities toward TEAD.
(E) ITC measurement of the affinity (Kd) between TEAD and niflumic acid (NA).
(F) The minimal energy conformations of FA and NA are shown as grey sticks. T
conformation of NA are shown as pink sticks.
2082 Structure 23, 2076–2086, November 3, 2015 ª2015 Elsevier Ltdusing qPCR. Our data indicated that the expression of these
genes did indeed increase in YAP S127A overexpressing cells
(Figure5F).Again,weobserved that theFA treatment in thesecells
reduced the expression levels of both Axl and NF2 (Figure 5F).
Interestingly, TEAD YBD has a fold similar to that of PDEd and
RhoGDI, which can solubilize the lipid moieties of guanosine tri-
phosphatases, suchasRasandRho (Figure6A). In theseproteins,
farnesyl or geranylgeranyl lipid groups from Ras or Rho also
occupy a hydrophobic central pocket similar to that of TEAD.
We hypothesize that a fully functional TEAD-YAP transcriptional
complex requires the association of TEAD with an unknown lipi-
dated regulator whereby the lipid group of this protein occupies
the central pocket of TEAD. This interaction is disrupted when
small-molecule inhibitors, such as flufenamates, occupy the cen-
tral pocket of TEAD (Figure 6A), which, in turn, compromises the
TEAD-YAP function.Wepropose that the inhibition of TEADactiv-
ity observed in our cellular assays is largely due to the binding of
flufenamates to the central pocket of TEAD. However, we cannot
completely rule out the possibility that the second flufenamate-
binding site, which is close to the interface-3 region of TEAD,
could play a synergistic role in inhibition. Fenamate analogs could
also be potentially used as a tool to disrupt TEAD-YAP interac-
tions. The entrance of the central pocket of TEAD is close to the
surface where YAP interacts with TEAD. Fenamate analogs,
such as the one shown in Figure 6B, span the central pocket of
TEAD and further extend to the surface at the TEAD-YAP inter-
face. It would be of great interest to test whether any of these an-
alogs could disrupt TEAD-YAP interactions.
In summary, we have shown that specific targeting of the hy-
drophobic central pocket of TEADs is conceptually and bio-
chemically feasible. A similar approach has been successfully
used to disrupt the interaction between PDEd and KRAS. Com-
pounds that can disrupt the PDEd-KRAS interaction have been
shown to have great potential for treating pancreatic cancers
(Zimmermann et al., 2013). This provides a strong incentive for
the development of potent small-molecule inhibitors that specif-
ically target the central pocket of TEADs. These inhibitors can
potentially be used to suppress the oncogenicity of YAP by dis-
rupting the TEAD activity.
EXPERIMENTAL PROCEDURES
Purification of TEAD4 YBD
The YBD domain of TEAD4, residues 217–434, was expressed as aHis-tagged
protein in BL21 (DE3) cells. The protein was purified using a two-stephe conformation of FA in the crystal structure of TEAD2-FA and the docked
All rights reserved
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Figure 5. Biological Consequence of Fena-
mate Binding to TEADs
(A) Native gel showing that the binding of TEAD to
fluorescently labeled YAP peptide is unaffected in
the presence of the flufenamate drugs.
(B) Significant reduction in the TEAD reporter ac-
tivity was observed after the treatment of cells with
flufenamic acid (FA) and niflumic acid (NA). Ctl,
control.
(C) The expression of Hippo-responsive genes,
such as NF2, Axl, and Jagged-1, were greatly
reduced after FA treatment. However, no signifi-
cant decrease was observed when the cells were
treated with mefanamic acid (MA).
(D) Migration of HEK293 cells was measured after
FA and NA treatments using a transwell assay. The
cells that migrate across the membrane were
visualized using crystal violet staining. The quan-
tification is shown below.
(E) Proliferation of HEK293 cells was measured
after treatment with FA and NA.
(F) The qPCR data show that FA reduces the
expression of genes, such as Axl and NF2, that are
stimulated upon YAP overexpression.
All the error bars represent SD.procedure, using immobilized metal-ion affinity chromatography and size-
exclusion chromatography. TEAD dm and TEAD2 YBD were also purified
using the same procedure. With the exception of crystallography, the YBD
domain of TEAD4 was used in all our assays. TEAD4 YBD did not crystallize
either alone or in the presence of drugs. For this purpose the YBD domain of
TEAD2, residues 217–447, was used.
Isothermal Titration Calorimetry
ITC experiments were performed on an Auto-iTC200 instrument fromMicrocal
at 25C. TEAD in 20 mMHEPES, 150 mMNaCl, and 2 mM 2-mercaptoethanol
at pH 7.5 was loaded into the ITC cell at concentrations of 100–120 mM with
5% (v/v) DMSO solution. Ligands in concentrations of 2.5–5 mM were dis-
solved in the same buffer/DMSO solution and auto-loaded into the syringe.
Each titration was carried out with 18 injections of 2.4 ml performed over a
period of 30 min with stirring at 1,000 rpm. Commercial ligands were pur-
chased from Sigma Aldrich, VitasM Laboratories, Ark Pharm, and Enamine.
Differential Scanning Fluorimetry
Thermal shift experiments were performed on a Roche LC480 PCRmachine in
a 384-well plate format. Fragments were tested at concentrations of 5 mM,Structure 23, 2076–2086, November 3, 2015and Pharmakon library compounds were tested
at concentrations of 20 mM. Each well consisted
of 4 mM TEAD and SYPRO orange.
STD NMR
STD NMR experiments were performed on a
Bruker 600-MHz NMR machine equipped with a
cyroprobe. FA at 2.5 mM was prepared in a buffer
containing 20 mMHEPES, 150mMNaCl, and 10%
D2O. The proton NMR experiment with water sup-
pression was collected and processed using
Topspin (2.1). STD experiments were conducted
in the absence and presence of 30 mM TEAD4.
Crystallization and Data Collection
Purification of recombinant human TEAD2 YBD
was carried out as previously described (Tian
et al., 2010). PurifiedTEAD2YBDwasconcentrated
to 4 mg/ml in a buffer containing 20 mM Tris(pH 8.0), 100 mM NaCl, 2 mM MgCl2, 1 mM tris(2-carboxyethyl)phosphine,
and 5% glycerol (v/v). The TEAD2 YBD domain was crystallized at 20C using
the hanging-drop vapor-diffusion method with a reservoir solution containing
0.1 M HEPES (pH 7.2) and 2.4 M sodium formate. The crystals were soaked
and cryoprotected with reservoir solution supplemented with 3 mM inhibitors
(FA or BFA) and 25% glycerol (v/v) for 1 hr, then flash-cooled in liquid nitrogen.
Crystals exhibited the symmetry of space group C2 and contained two mole-
cules per asymmetric unit. Diffraction data were collected at beamline 19-ID
(SBC-CAT) at the Advanced Photon Source at Argonne National Laboratory,
Argonne, Illinois, and processed with HKL3000. Phases were obtained by mo-
lecular replacement with Phaser (McCoy et al., 2007) using the crystal structure
of humanTEAD2YBDdomain (PDB: 3L15) as the searchmodel. Iterativemodel
building and refinements were carried out with Coot and PHENIX, respectively
(Adams et al., 2010; Emsley et al., 2010). The dataset for TEAD2-BFA was
collected at awavelength near the absorption edge of bromine. Bromide atoms
in the bound BFA molecules were confirmed from peaks in the anomalous dif-
ferencemap createdwith data truncated to 4.5 A˚ resolutionwithout refining the
structure. Thefinalmodel for TEAD2-FA (Rwork =17.1%,Rfree = 22.4%)contains
401 residues, 85 water molecules, and three FA molecules. The final model for
TEAD2-BFA (Rwork = 17.9%, Rfree = 22.7%) contains 401 residues, 109 waterª2015 Elsevier Ltd All rights reserved 2083
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Figure 6. TEAD and PDEd Have a Similar Hydrophobic Central
Pocket
(A) Superposition of TEAD-FA and PDEd-farnesyl (PDB: 3T5I) complexes.
Farnesyl (shown as orange sticks) and FA (shown as pink sticks) occupy the
central pocket of PDEd and TEAD, respectively.
(B) A structural model to show that a fenamate analog (gray sticks) extends
from the central pocket to interfere with TEAD-YAP interaction (red ellipse). A
propyne substituent was added ortho to the acid of FA and the compound was
docked onto the TEAD1-YAP complex (PDB: 3KYS). Bulky substituents in this
position may disrupt YAP binding.molecules, and three BFA molecules. MolProbity was used for structure
validation to show that all models have good geometry (Davis et al., 2007).
Data collection and structure refinement statistics are summarized in Table 1.
All structural figures were generated with the Schrodinger software suite or
Chimera (UCSF) (Pettersen et al., 2004).
Molecular Modeling
The protein-ligand complexes were prepared using the protein preparation
wizard in Maestro (Schro¨dinger). This included adding hydrogens, removing
water molecules beyond 5 A˚ from the ligand, and optimizing the hydrogen-
bonding network. Finally, the complex was relaxed using the OPLS-2005 force
field and the restrained minimization procedure of the protein preparation
wizard. The resulting conformation of the ligand was taken as the bioactive
conformation. The global energy conformation was found by conformational
search using MacroModel (Schro¨dinger), the OPLS-2005 force field, GB/SA
solvation model, and torsional sampling. The search was continued until all
low-energy conformations were found at least ten times. The global energy
minimum was found to be within 2 kJ/mol of the conformation obtained by
minimizing the bioactive conformation. 2 kJ/mol is within the uncertainty of
the method. Density functional theory calculations were done using the Jaguar
(Schro¨dinger) PBF (Poisson Boltzmann Finite element) solvation model with
water as solvent, and the basis sets are listed in Table 2. Grid density was
set to Fine and accuracy level to Accurate. For each bioactive conformation,
two optimizations were done, one full optimization and one with all torsions
constrained. The strain energy was found by subtracting the energy of the fully
optimized bioactive conformation from that of the bioactive conformation
optimized with constraints.
Luciferase Reporter Assay
HEK293 cells were grown at 37C in the presence of 5% CO2 in DMEM sup-
plemented with 10% fetal bovine serum (FBS) and antibiotic-antimycotic
(Life Technologies). TEAD activity reporter developed by Dupont et al. (2011)
was used in the assay. Cells in a 6-cm dish were transfected with 150 ng of
TEAD firefly luciferase and 25 ng of CMV Renilla luciferase constructs. The
cells were incubated with FA (150 mM) or NA (150 mM) overnight. At 150 mM
concentration, the TEAD activity was inhibited by 50%. Luciferase assay
was performed using the Promega Dual luciferase assay kit according to the
manufacturer’s guidelines.
Western Blot
The antibodies used in the western blot in this study include NF2 (D1D8), Axl
(C2B12), and Jagged1 (28H8) from Cell Signaling Technology; and actin (C4)
from Santa Cruz Biotechnology.2084 Structure 23, 2076–2086, November 3, 2015 ª2015 Elsevier LtdMigration Assay
HEK293 cells were treated with 150 mM FA or NA, and serum-starved over-
night. Around 18,000 cells were seeded into the transwell inserts (BD BioCoat,
control inserts) in triplicates. The inserts were immersed in DMEM supple-
mented with 10% FBS, and the cells were allowed to migrate overnight. The
membranes were then washed in PBS and fixed in 4% paraformaldehyde.
The migrated cells were visualized through staining with 1% crystal violet.
qPCR
The following TaqMan probes were used: Axl, Hs01064444_m1; NF2,
Hs00966302_m1; 18S, Hs03003631_g1. The qPCR assay was performed
according to the manufacturer’s guidelines.
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